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Background: Patients undergoing major orthopaedic surgery (MOS), such as total hip (THR) or total knee
replacement (TKR), are at high risk of developing venous thromboembolism (VTE). For thromboembolism
prophylaxis, the oral anticoagulant rivaroxaban has recently been included in the German diagnosis related group
(DRG) system. However, the cost-effectiveness of rivaroxaban is still unclear from both the German statutory health
insurance (SHI) and the German hospital perspective.
Objectives: To assess the cost-effectiveness of rivaroxaban from the German statutory health insurance (SHI)
perspective and to analyse financial incentives from the German hospital perspective.
Methods: Based on data from the RECORD trials and German cost data, a decision tree was built. The model was
run for two settings (THR and TKR) and two perspectives (SHI and hospital) per setting.
Results: Prophylaxis with rivaroxaban reduces VTE events (0.02 events per person treated after TKR; 0.007 after THR)
compared with enoxaparin. From the SHI perspective, prophylaxis with rivaroxaban after TKR is cost saving
(€27.3 saving per patient treated). However, the cost-effectiveness after THR (€17.8 cost per person) remains unclear
because of stochastic uncertainty. From the hospital perspective, for given DRGs, the hospital profit will decrease
through the use of rivaroxaban by €20.6 (TKR) and €31.8 (THR) per case respectively.
Conclusions: Based on our findings, including rivaroxaban for reimbursement in the German DRG system seems
reasonable. Yet, adequate incentives for German hospitals to use rivaroxaban are still lacking.
Keywords: ‘Clinical course of venous thromboembolism’, ‘Major orthopaedic surgery’, ‘Thromboembolic
prophylaxis’, ‘Cost-effectiveness analysis’Background
Patients undergoing major orthopaedic surgery (MOS),
such as total hip (THR) or total knee replacement (TKR),
are at high risk of developing a venous thromboembolism
(VTE). MOS belongs to the type of surgery with the high-
est VTE incidence among cardiothoracic and vascular sur-
gery [1–3]. Serious VTE complications such as deep vein
thrombosis (DVT) and pulmonary embolism (PE) usually* Correspondence: bjoern.stollenwerk@helmholtz-muenchen.de
2Helmholtz Zentrum München (GmbH), Institute of Health Economics and
Health Care Management, Ingolstädter Landstraße 1, 85764, Neuherberg,
Germany
Full list of author information is available at the end of the article
© 2012 Zindel et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordevelop within the first 3 months after surgery. In the ab-
sence of prophylaxis after hip arthroplasty, a 44% DVT
risk has been reported. This was accompanied by a 3% PE
risk with an all-risk mortality of 0.7% [2].
Especially at onset, VTEs may be clinically asymptom-
atic, making early diagnosis difficult. Therefore, routine
primary prophylaxis in patients at risk of VTE is desig-
nated as a grade 1A recommendation in international
guidelines [1]. For patients undergoing elective hip or knee
arthroplasty, the American College of Chest Physicians
recommends low-molecular-weight heparins (LMWHs),
fondaparinux or a vitamin K antagonist up to 35 days after
surgery. In Germany, the Association of the ScientificLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tlichen Medizinischen Fachgesellschaften’, AWMF) guide-
lines recommend short-term 2-week prophylaxis for
patients undergoing TKR and extended 5-week prophy-
laxis for those undergoing THR [4].
Currently, LMWHs are often used for DVT prophy-
laxis in Germany, in particular subcutaneous (s.c.) appli-
cation of enoxaparin sodium, an antithrombin III-
dependent inhibitor of factors Xa and IIa [5–7]. Because
of heparin-induced thrombocytopenia (HIT), a poten-
tially fatal complication of enoxaparin sodium treatment
[8], laboratory monitoring for thrombocytes is essential.
Another prophylaxis option is rivaroxaban (BAY 59–
7939). In Germany, it has been marketed since October
2008 as XARELTOW and licensed for the primary pre-
vention of postoperative thrombotic events after THR
and TKR in adult patients. Rivaroxaban is an active, dir-
ect and selective antithrombin-independent factor Xa in-
hibitor. It is one of the first anticoagulation variants
available in oral form. Because of its pharmacodynamic
profile, no dosage adjustment – independent of the
patient’s age, gender, body weight, or in patients with
mild renal impairment – is needed [9]. It is safe to ad-
minister only one daily dose of rivaroxaban, and no spe-
cific monitoring is required [10].
Even though there are other oral active anticoagulants
available for this indication, such as dabigatran etexilate,
we chose enoxaparin sodium as the comparator when
determining the cost-effectiveness of rivaroxaban. This
choice was made because of the widespread and com-
mon use of enoxaparin sodium in German hospitals.
The efficacy of rivaroxaban has been shown in the ran-
domized, double-blind phase III RECORD trials 1–4
published in 2008 and 2009 [11–14], which compared
rivaroxaban with enoxaparin sodium in thromboembolic
VTE prophylaxis strategies after MOS. Although rivar-
oxaban was superior to enoxaparin in preventing VTE
events in all trials, no differences were found in the oc-
currence of major bleeding events [15].
Reimbursement of THR and TKR cases for German
hospitals is based on diagnosis related groups (DRGs)
[16]. DRGs are a hospital reimbursement system that
classifies diagnoses with similar resource use into the
same categories. Hospitals are then paid a lump sum for
each case, which is calculated by the Institute for the
Hospital Remuneration System (‘Institut für das Entgelt-
system im Krankenhaus’, InEK [16,17]) based on the
average real resource use of selected hospitals. Since the
beginning of 2011, in addition to enoxaparin sodium,
rivaroxaban resource use has been weighted in the Ger-
man DRG calculation scheme for THR and TKR. This
means that if all hospitals initially used enoxaparin but
later on collectively switched to rivaroxaban, the amount
of money associated with the corresponding DRG wouldchange in the long run. In such a case, the additional
costs of rivaroxaban would be reimbursed implicitly.
However, as the prescription pattern of hospitals
depends on multiple conditions including but not lim-
ited to financial incentives, it is unclear whether changes
in these patterns will be reimbursed.
Meanwhile, it has not yet been assessed whether reim-
bursement of rivaroxaban is cost-effective from the Ger-
man SHI perspective. Also, it remains unclear whether
financial incentives exist for German hospitals to switch
from enoxaparin sodium to rivaroxaban. As the treat-
ment costs with rivaroxaban exceed the treatment costs
with enoxaparin sodium, but no additional costs are
reimbursed per case, one may assume that prescribing
rivaroxaban is not attractive from the hospital perspec-
tive. However, as a result of the RECORD studies, cases
of VTE events can be avoided with rivaroxaban, which
reduces hospital expenditure. Given the higher efficacy
of rivaroxaban compared with enoxaparin sodium, Ger-
man hospitals have to weigh the savings of avoided
VTEs against the additional drug costs of rivaroxaban.
To analyse the cost-effectiveness of rivaroxaban com-
pared with enoxaparin sodium in patients undergoing
THR and TKR from the SHI perspective in Germany, a
decision analytic model was built. Additionally, financial
incentives were evaluated for German hospitals in
switching from enoxaparin sodium to rivaroxaban.
Methods
The model
A decision tree was built to evaluate the cost-
effectiveness of rivaroxaban versus enoxaparin sodium
for thromboprophylaxis in patients undergoing THR
and TKR (Figure 1). The health outcome was measured
as the number of DVTs averted. All costs were measured
in 2010 euros. For the analyses from the SHI perspec-
tive, we assumed that the SHI reimburses additional
costs associated with the treatment of rivaroxaban. To
cover the 90-day risk period for the development of
postoperative VTE complications, a time horizon of
3 months after surgery was chosen [18]. In this period,
all events developing during hospitalization or after dis-
charge were included. All pathways were based on con-
ditional probabilities reflecting the clinical course of
VTE complications after MOS [2,18–23].
All patients undergoing THR and TKR are at risk of
prophylaxis-related bleeding events as well as the devel-
opment of a DVT or PE after surgery. All VTE events
were specified by their time of incidence, whether occur-
ring during primary hospitalization (i.e. ‘pre-discharge’)
or after release from hospital (i.e. ‘post-discharge’) lead-
ing to a hospital re-admission. Irrespective of a pre- or
post-discharge VTE event, patients receive outpatient
follow-up treatment after hospital discharge.
Figure 1 Decision analysis tree: patient outcomes during a period from surgery to 3 months postoperatively.
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DVT can occur. Furthermore, all DVTs were classified as
asymptomatic (i.e. clinically unapparent) or symptomatic
(i.e. clinically apparent) events. After prophylaxis stops,
an asymptomatic DVT can change into a symptomatic
VTE [20]. If a symptomatic PE is not diagnosed and trea-
ted in time, it can be fatal.
The decision tree was programmed using TreeAge
Pro 2008W software (Data 3.5; TreeAge Software Inc.,
Williamstown, MA, USA). For statistical analyses and to
assess parameter uncertainty, the software package R was
used [24].
Clinical model parameters
The probabilities of surgery-related complications such
as major bleeding, distal and proximal DVT, non-fatal
PE and death from any cause during the on-treatment
period are based on the RECORD trials 1 and 3 [11,13].
In these multicentre, randomized, controlled, double-
blind and double-dummy phase III clinical trials, rivar-
oxaban was compared with enoxaparin sodium in terms
of effectiveness and safety in thromboprophylaxis in
12,729 patients. The primary endpoint was a composite
of any DVT, non-fatal PE and death from any cause.
Safety was stated in the number of prophylaxis-related
major bleeding events.
The division of VTE events into ‘pre-discharge’ and
‘post-discharge’ was derived from previously published
data [18]. The subdivision into symptomatic or asymptomaticDVT events as well as the VTE-dependent deaths are based
on the proportions reported in the Advisory Committee
Briefing Book for rivaroxaban [25]. Finally, the prob-
ability of an asymptomatic DVT becoming symptom-
atic was derived from previously published data [18,20].
The corresponding model parameters are summarized
in Table 1.Resource consumption and costs
With respect to the chosen perspectives, only direct
costs are considered in our analysis. Clinical pathways
for the prophylaxis, diagnosis and treatment of VTE
events are based on nationally accepted AWMF guide-
line recommendations [4,19] and aligned with inpatient
clinical protocols from available studies [26–28].
For the analysis, it was assumed that every patient
receives adequate prophylaxis and, in the case of a
symptomatic non-fatal VTE event, adequate diagnostic
and treatment management. As 90% of patients with
fatal PE die within the first 2 hours after its development
[19], we assumed that these patients are not treated and
incur no additional costs. Likewise, we expected asymp-
tomatic DVTs and PEs to remain undetected and did
not consider additional costs. Because there was no sig-
nificant difference between major bleeding events in
both the intervention and the control groups in the
RECORD trials [15], the costs of major bleeding events
were not considered in our analysis.
Table 1 Summary of parameter distributions for probabilities used in the PSA
Expected values of probabilities Parameter Expected value (standard error) Source
after THR after TKR
Prophylaxis with enoxaparin
Major bleeding par_1 0.002 (0.0006) 0.005 (0.0015) [11,13]
VTE event par_2 0.035 (0.0047) 0.187 (0.0132) [11,13,25]
Pre-discharge VTE1 par_3 0.240 (0.0181) 0.530 (0.0221) [18]
DVT par_4 0.964 (0.0252) 0.976 (0.0120) [11,13,25]
Distal DVT par_5 0.415 (0.0677) 0.875 (0.0007) [11,13,25]
Symptomatic DVT par_6 0.167 (0.0507) 0.122 (0.0256) [11,13,25]
Asymptomatic DVT becomes symptomatic par_7 0.200 (0.1789) 0.048 (0.0466) [20]
Non-fatal PE par_8 0.500 (0.3536) 0.875 (0.1654)² [11,13,25]
Prophylaxis with rivaroxaban
Major bleeding par_1 0.002 (0.0006) 0.005 (0.0015) [11,13]
VTE event par_9 0.010 (0.0025) 0.096 (0.0103) [11,13,25]
Pre-discharge VTE1 par_3 0.240 (0.0181) 0.530 (0.0221) [18]
DVT par_10 0.750 (0.1083) 0.994 (0.0089)² [11,13,25]
Distal DVT par_11 0.917 (0.0798) 0.886 (0.0358) [11,13,25]
Symptomatic DVT par_12 0.250 (0.1250) 0.099 (0.0331) [11,13,25]
Asymptomatic DVT becomes symptomatic par_7 0.200 (0.1789) 0.048 (0.0466) [20]
Non-fatal PE par_13 0.875 (0.1654)² 0.500 (0.5000)² [11,13,25]
PSA =probabilistic sensitivity analysis, VTE = venous thromboembolism, DVT = deep vein thrombosis, PE = pulmonary embolism.
1Values are independent of prophylactic drug.²If the point estimate yielded to 0 or 1, half an event was added or subtracted to receive reasonable distributions
for probabilistic sensitivity analysis.
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Based on current AWMF guidelines [4], prophylaxis after
THR is recommended for 28–35 days and for 11–14 days
after TKR. We assumed a mean prophylaxis time of
32 days and 13 days respectively. Whereas prophylaxis
with s.c. enoxaparin sodium (40 mg once a day) is initiated
on the day before surgery, rivaroxaban (10 mg daily) treat-
ment starts on the day of surgery [4,11,13]. The duration
of prophylaxis is limited depending on the occurrence of a
bleeding complication or a VTE event. In the case of a
prophylaxis-related major bleeding event during the initial
treatment period, it is assumed to occur on day 5 of the
hospital stay [27] and prophylaxis is stopped immediately.
In the case of a pre-discharge VTE event (including DVT,
non-fatal PE or fatal PE), it is assumed to occur on day 7
after surgery; prophylaxis is stopped and VTE treatment is
initiated [28]. Only in the case of a post-discharge VTE
event or in the absence of both a VTE event and a major
bleeding event is the whole recommended prophylaxis
duration (32 days after THR and 13 days after TKR) admi-
nistered to the patient.
Costs of thromboembolic prophylaxis in hospital with
enoxaparin sodium (i.e. drug costs, nursing time and pa-
tient education for s.c. injections, needle equipment and
monitoring) were not calculated separately, as they are
already included in the DRG revenues for THR and TKR
[16]. Additional drug costs for rivaroxaban prophylaxis inhospital were derived from the ‘Rote Liste’, a bi-annually
updated German medical drug register that provides med-
ical professionals with summaries of drug characteristics,
wholesale prices and patient information leaflets [29]. The
additional drug price for rivaroxaban (€7.09) compared
with enoxaparin (€4.49) was calculated as the difference in
price between the drugs (€2.60) and multiplied by the days
of prophylaxis duration (see Table 2).
Costs of prophylactic drugs after hospital discharge (€6.88
for rivaroxaban and €5.44 for enoxaparin) were based on the
National Association of Statutory Health Insurance Physi-
cians (‘Kassenärztliche Bundesvereinigung’, KBV) [30] data.
In conjunction with the health insurance funds, it devises
and revises an office-based doctors’ fee schedule for the out-
patient cost sector, the so-called German Uniform Assess-
ment Standard (‘Einheitlicher Bewertungsmaßstab’, EbM)
[30]. Drug prices per day are multiplied by the number of
days the patient receives prophylaxis after discharge from
hospital. Because of immediate prophylaxis withdrawal in the
case of a pre-discharge VTE or major bleeding event, there is
no further prophylactic drug consumption after discharge
from hospital. Prophylaxis duration and associated costs are
summarized in Table 2.
Additional costs of prophylaxis with rivaroxaban during
hospitalization and pre-discharge VTE management are at
the hospital’s expense. In contrast, costs of outpatient
prophylaxis and outpatient therapy for pre-discharge VTE
Table 2 Prophylaxis duration and costs in hospital and after discharge (costs in 2010 euros)
Days of prophylaxis
duration
Non-DRG included costs (€) for prophylaxis Source
Enoxaparin sodium3 Rivaroxaban
In hospital (total duration) Costs for hospitals
MB with or without VTE1
- after THR- after TKR
5.0 (5)5.0 (5) 0.000.00 13.0013.00 [4,16,27,29]
Pre-discharge VTE without MB²
- after THR- after TKR
7.0 (7)7.0 (7) 0.000.00 18.2018.20 [4,16,28,29]
Post-discharge VTE or no VTE and no MB
- after THR- after TKR
12.4 (32)12.7 (13) 0.000.00 32.2433.02 [4,16,28,29]
After discharge (total duration) Costs for SHI
Post-discharge VTE or no VTE and no MB
- after THR- after TKR
19.6 (32)0.3 (13) 106.621.63 134.852.06 [4,30]
DRG=diagnosis related groups, MB=major bleeding, THR = total hip replacement, TKR = total knee replacement, VTE = venous thromboembolism, SHI = social
health insurance.
1A major bleeding event was assumed to occur on day 5 of the hospital stay and prophylaxis is stopped immediately.
²A pre-discharge VTE event was assumed to occur on day 7 after surgery and prophylaxis is stopped.
3The hospital costs for enoxaparin sodium are included in the DRGs.
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bursed by the SHI.Diagnostics and treatment for pre-discharge VTE events
All pre-discharge VTE events including fatal PE were
assumed to occur on day 7 after surgery [28]. To con-
firm a diagnosis of DVT, the costs of D-dimer testing
and a Doppler ultrasound examination were included
[19]. For diagnosis of a clinically apparent PE, blood gas
analysis, D-dimer testing, chest X-ray, electrocardio-
gram, echocardiography and a computerized tomog-
raphy (CT) scan were conducted [19].
In the case of a confirmed VTE, AWMF guidelines
recommend phenprocoumon, a derivative of coumarin,
for 3 months [4]. As the initial period of treatment with
coumarin is associated with a procoagulant state, simul-
taneous LMWH treatment is administered until anticoa-
gulation is effective [19]. In our analysis, it was assumed
that patients would receive enoxaparin sodium twice a
day for 6 days including thrombocyte monitoring, mak-
ing further regular outpatient visits after discharge from
hospital necessary. For each patient with DVT or PE,
compression therapy is started in hospital and continued
after discharge [4]. Prices for in-hospital diagnostic and
treatment management are taken from the university
teaching hospital in Cologne, Germany. Prices for med-
ical drugs are derived from the ‘Rote Liste’ [29]. Costs of
outpatient VTE follow-up therapy are based on the
EbM [30].Additional length of stay for pre-discharge VTE events
As the incidence of a non-fatal pre-discharge VTE event
requires extended hospitalization on a general ward,
additional hospital days were considered. These additionalhospital days (i.e. after THR: 3.9 days for DVT, 4.6 days for
non-fatal PE; after TKR: 3.3 days for DVT, 6.0 days for
non-fatal PE) [26] were added to the mean hospitalization
time after THR (12.4 days) and TKR (12.7 days) based on
the specific DRG for THR and TKR [16]. In the case of PE,
it was assumed that patients would spend on average 1 day
in the intensive care unit.
In the German DRG system, a hospital receives reim-
bursement for THR or TKR irrespective of the hospital
duration between 4 and 18 days [31]. In the German
healthcare system, costs for the mean hospitalization
time after THR and TKR are covered by the DRG reim-
bursement. The hospital receives a fixed revenue irre-
spective of a hospital duration between 4 and 18 days
[31]. Beyond this timeframe, the DRG revenue increases
gradually per day. For all pre-discharge VTE complica-
tions in our analysis – except in the case of a non-fatal
PE after TKR – the extended hospitalization is within
this range, and costs for additional hospital days as well
as further treatment management are carried by the hos-
pitals themselves [31]. Only in the case of a non-fatal PE
after TKR is an extended hospitalization time of
18.7 days in total required. In this case, the hospital
receives a slightly higher DRG revenue.
Average daily hospital costs were approximated based
on the average DRG reimbursement per hospital day
[16]. Resource consumption and costs of pre-discharge
VTE events are listed in Table 3.Diagnostics and treatment for post-discharge VTE events
We assumed that every ‘post-discharge’ DVT leads to hos-
pital admission. In the case of a fatal PE, it was assumed that
death would occur on the day of re-admission. All diagnostic
and therapeutic measures including re-admissions to hospital
Table 3 Resource consumption and costs (€) of pre-discharge venous thromboembolism incurred in hospital and after
discharge (outpatient) (costs in 2010 euros)












Blood gas analysis 0.0 0.0 1.0 1.0 4.95 [19,27,28], UTHC
D-dimer 1.0 1.0 1.0 1.0 9.90 [19,27,28], UTHC
Doppler ultrasound 1.0 1.0 0.0 0.0 9.90 [19,27,28], UTHC
Chest X-ray 0.0 0.0 1.0 1.0 7.70 [19,27,28], UTHC
ECG 0.0 0.0 1.0 1.0 8.36 [19,27,28], UTHC
CT 0.0 0.0 1.0 1.0 154.00 [19,27,28], UTHC
Echocardiography 0.0 0.0 1.0 1.0 27.50 [19,27,28], UTHC
Treatment
Enoxaparin sodium 12.0 12.0 12.0 12.0 9.98 [19,27–29]
Subcutaneous injection 12.0 12.0 12.0 12.0 2.20 [19,27,28], UTHC
Blood sample (TZ) 1.0 1.0 1.0 1.0 5.50 [19,27,28], UTHC
Phenprocoumon (days) 10.3 10.0 11.0 12.7 0.17 [19,27–29]
Anticoagulant monitoring1 2.0 2.0 2.0 2.0 8.80 [19,27,28], UTHC
Compression therapy 1.0 1.0 1.0 1.0 5.23 [19,27,28], UTHC
Additional LOS2 (€) 1,086.27 919.15 1,716.45 1,973.73 [4,16,19,26]
Total costs for hospital (€) 1,282.27 1,115.14 2,105.22 2,362.79
In hospital Extra DRG reimbursement³ 0 0 0 191.46
Outpatient Treatment
Outpatient visit4 1.0 1.0 1.0 1.0 53.16 [19,27,28,30]
Phenprocoumon (days) 79.7 80.0 79.0 77.3 0.17 [19,27,28,30]
INR measurement 10.0 10.0 10.0 10.0 1.68 [19,27,28,30]
Compression stockings 2.0 2.0 2.0 2.0 36.90 [19,27,28,30]
Total costs for health insurance (€) 157.35 157.40 157.23 348.40
DVT =deep vein thrombosis, THR = total hip replacement, TKR = total knee replacement, nf PE = non-fatal pulmonary embolism, ECG= electrocardiogram,
CT = computerized tomography with contrast agent, TZ = thrombocytes, LOS = length of stay, UTHC=University teaching hospital in Cologne, Germany.
1Including blood sample and INR (international normalized ratio) measurement.
²Additional hospital days are derived from Tilleul et al. [26] and calculated as 3.9 days for DVT and 4.6 days for non-fatal PE after THR;
3.3 days for DVT and 6.0 days for non-fatal PE after TKR.
³DRG reimbursement for an extended hospital stay beyond 18 days.
4Flat rate including all outpatient visits and blood samples every quarter (3 months).
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weighted specific DRG reimbursement for DVT and PE [16].
Resource consumption and costs of post-discharge VTE
events are listed in Table 4.Cost-effectiveness analysis and probabilistic sensitivity
analysis
To accommodate the different settings (THR versus
TKR) and perspectives (SHI versus hospital), four modi-
fications of the model were run. The main model out-
comes are defined as incremental costs and incremental
effects, estimated by averaging the corresponding values
resulting from probabilistic sensitivity analysis (PSA).To reflect parameter uncertainty [32,33], a probabilistic
analysis with 1,000 iterations was performed, in which all
costs were assumed to be Gamma distributed and prob-
abilities to be Beta distributed (Tables 1 and 5). Para-
meters of the Gamma and the Beta distributions were
approximated based on the corresponding expected value
and standard error. As there were no reliable stochastic
estimates for the standard errors of costs, we applied 10%
of the corresponding costs as the standard error for each
cost parameter. The results of the PSA are displayed as a
scatterplot of incremental costs and incremental effects
and as cost-effectiveness acceptability curves.
To estimate the impact of individual parameters on
the results of the analysis, we performed an analysis of
Table 4 Resource consumption and costs (€) of post-discharge VTE events after THR and TKR from the social health
insurance perspective (costs in 2010 euros)
Resources DVT² (units) Non-fatal PE² (units) Fatal PE³(units) Unit prices(€) Source
In hospital Diagnosis, treatment and hospitalization (€) 1,838.33 3,543.48 1,256.43 [16]
Outpatient Treatment
Outpatient visit1 1.0 1.0 0.0 53.16 [19,27,28,30]
Phenprocoumon (days) 83.4 79.7 0.0 0.17 [19,27,28,30]
INR measurement 10.0 10.0 0.0 1.68 [19,27,28,30]
Compression stockings 2.0 2.0 0.0 36.90 [19,27,28,30]
Total costs for health insurance (€) 1,995.89 3,700.43 1,256.43
VTE = venous thromboembolism, THR = total hip replacement, TKR = total knee replacement, DVT = deep vein thrombosis, PE = pulmonary embolism.
1Flat rate including all outpatient visits and blood samples every quarter (3 months).
²It was assumed that every post-discharge DVT and PE leads to hospital admission.
³In the case of a fatal PE, it was assumed that death would occur on the day of re-admission.
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proportion of the sum of squares in the output para-
meters (i.e. incremental costs and incremental effects)
explained by the variation in each input parameter was
identified. Furthermore, univariate deterministic sensitiv-
ity analysis has been performed for parameters that were
identified as greatly affecting the results.
Results
Prophylaxis with rivaroxaban prevents on average 0.020
VTE events per person treated after TKR (95% CI: [0.007;
0.036]) and 0.007 events per person treated after THR
(95% CI: [−0.0005; 0.018]). From a hospital perspective,
rivaroxaban reduces the profit by €20.6 per person treated
in the case of TKR (95% CI: [€9.3; €31.4]) and by €31.8Table 5 Summary of parameter distributions for costs (in 201
Costs of resources Parameter Expected costs
After THR
Hospital perspe
Prophylaxis costs with enoxaparin in the case of
Post-discharge VTE or no VTE and no MB par_14 0
Prophylaxis costs with rivaroxaban in the case of
MB with or without VTE par_15 13.00 (1.30)
Pre-discharge VTE without MB par_16 18.20 (1.82)
Post-discharge VTE or no VTE and no MB par_17 32.24 (3.22)
Total costs of pre-discharge VTE
DVT par_18 1,282.27 (128.
Non-fatal PE par_19 2,105.22 (210.
Total costs of post-discharge VTE
DVT par_20 0
Non-fatal PE par_21 0
Fatal PE par_22 0
PSA =probabilistic sensitivity analysis, THR = total hip replacement, TKR = total knee
MB=major bleeding, DVT = deep vein thrombosis, PE = pulmonary embolism.(95% CI: [€25.5; €38.7]) in the case of THR. From the SHI
perspective, prophylaxis with rivaroxaban is dominant in
TKR: direct costs are reduced by €27.3 (95% CI: [€9.6;
€51.6]) per person treated. In THR, however, prophylaxis
with rivaroxaban leads to non-significant additional costs
from the SHI perspective (i.e. €17.8, 95% CI: [−€20.7;
€55.6] per person treated). This results in an incremental
cost-effectiveness ratio of €875 per VTE event avoided.
The results after TKR are robust with respect to PSA:
from the SHI perspective, 99.8% of the simulated scenar-
ios are located in the lower right (i.e. dominant) quadrant
and, from the hospital perspective, 99.8% of the simulated
scenarios are located in the upper right quadrant (i.e. in-
creasing costs for hospitals) of the cost-effectiveness plane
(see Figure 2).0 euros) used in the PSA
(€) (standard error)
After TKR
ctive SHI perspective Hospital perspective SHI perspective
106.42 (10.64) 0 1.63 (0.16)
0 13.00 (1.30) 0
0 18.20 (1.82) 0
134.85 (13.49) 33.02 (3.30) 2.06 (0.21)
33) 157.35 (17.74) 1,115.14 (111.51) 157.40 (15.74)
52) 157.23 (15.73) 2,362.79 (236.28) 348.40 (34.84)
1,995.89 (199.59) 0 1,995.89 (199.59)
3,700.43 (370.04) 0 3,700.43 (370.04)
1,256.43 (125.64) 0 1,256.43 (125.64)
replacement, SHI = social health insurance, VTE = venous thromboembolism,







































































Figure 2 Scatterplot of incremental costs and effects.
Zindel et al. BMC Health Services Research 2012, 12:192 Page 8 of 14
http://www.biomedcentral.com/1472-6963/12/192The scatterplots of incremental costs and effects are
provided in Figure 2. Numerical estimates are provided
in Tables 6 and 7. With respect to THR, there is a wider
spread over the quadrants of the cost-effectiveness plane.
Prophylaxis with rivaroxaban reduces the number of
VTE events in 96% of the iterations of the PSA. From
the SHI perspective, the costs associated with rivaroxa-
ban are higher than the costs associated with enoxaparin
in 81.6% of the cases. In 18.3% of the cases, prophylaxis
with rivaroxaban was considered to be dominant over
prophylaxis with enoxaparin (i.e. lower right quadrant).Table 6 Results of the base case cost-effectiveness analysis (y
(standard errors in parentheses)
Type of surgery Costs (€) Incremental costs (€) VTE events per perso
THR
Rivaroxaban 33.8 (3.3) 31.8 (3.4) 0.005 (0.002)
Enoxaparin 2.05 (0.7) 0.012 (0.005)
TKR
Rivaroxaban 38.8 (3.9) 20.6 (5.6) 0.014 (0.005)
Enoxaparin 18.1 (4.3) 0.035 (0.009)
THR = total hip replacement, TKR = total knee replacement, VTE = venous thromboemThe cost-effectiveness acceptability curves
As hospitals may not strictly minimize their treatment
costs, but might balance additional treatment costs
against health gain, cost-effectiveness acceptability curves
are displayed for both the hospital and the SHI perspec-
tives (Figure 3). From the hospital perspective, the
probability of rivaroxaban being cost-effective differs
considerably between THR and TKR. From the SHI per-
spective, the cost-effectiveness acceptability curves start
significantly higher at a probability of 0 for a willingness-
to-pay threshold of €0 per event avoided, as incrementalear 2010 values) from the German hospital perspective
n Incremental effect (events avoided) ICER (€ per event avoided)
0.007 (0.005) 1,564
0.020 (0.007) 1,014
bolism, ICER = incremental cost-effectiveness ratio.
Table 7 Results of the base case cost-effectiveness analysis (year 2010 values) from the social health insurance
perspective (standard errors in parentheses)
Type of surgery Costs (€) Incremental costs (€) VTE events per person Incremental effect(events avoided) ICER(€ per event avoided)
THR
Rivaroxaban 146.5 (14.2) 17.8 (19.6) 0.005 (0.002) 0.007 (0.005) 875
Enoxaparin 128.7 (14.9) 0.012 (0.005)
TKR
Rivaroxaban 20.7 (9.0) −27.3 (10.7) 0.014 (0.005) 0.020 (0.007) dominant
Enoxaparin 48.0 (16.9) 0.035 (0.009)
THR = total hip replacement, TKR = total knee replacement, VTE = venous thromboembolism, ICER = incremental cost-effectiveness ratio.
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http://www.biomedcentral.com/1472-6963/12/192costs are negative in 99.8% (TKR) and 18.4% (THR) of the
cases (Figure 3).
The ANCOVA analysis and deterministic sensitivity
analysis
Within ANCOVA analysis, several parameters were
identified to explain a large proportion of the uncer-
tainty of the results (Figure 4). Deterministic sensitivity
analyses for the most influential parameters are pre-
sented in Table 8. The incremental effect (i.e. number of
VTE events avoided) after TKR was mostly affected by
the probability of a symptomatic DVT event after
prophylaxis with enoxaparin (Parameter 6). This param-
eter explained 37% of the total amount of the sum of
squares. The incremental effect after THR was mostly
affected by the probability that an asymptomatic DVT

































Figure 3 Cost-effectiveness acceptability curves.explained 64% of the total amount of the sum of
squares.
Incremental costs were mostly affected by the prophy-
laxis costs with rivaroxaban (Parameter 17). These
explained 92.1% of the incremental costs after THR and
34.2% after TKR from the hospital perspective. From the
SHI perspective, 48.2% of the incremental costs were
explained according to THR. However, with respect to
TKR from the SHI perspective, the probability that an
asymptomatic DVT becomes symptomatic (Parameter 7)
had the highest impact on the incremental costs (46.3%).
Discussion
Rivaroxaban was compared with enoxaparin sodium for
prophylaxis of venous thromboembolism after MOS in
the German healthcare setting. Based on a decision tree
model, we assessed the cost-effectiveness of rivaroxaban20 30 40















































































































Figure 4 Effect of single model parameters on the results. Most influential parameters: Parameter 6, probability of a symptomatic deep vein
thrombosis (DVT) event after prophylaxis with enoxaparin; Parameter 7, probability that an asymptomatic DVT becomes symptomatic; Parameter
17, prophylaxis costs with rivaroxaban
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http://www.biomedcentral.com/1472-6963/12/192from the SHI perspective and financial incentives from
the hospital perspective.
This is the first economic evaluation of rivaroxaban in
the German healthcare setting. A particular aspect of
our analysis is that we simultaneously evaluated two
perspectives: the German hospital perspective and the
German SHI perspective. This choice was made because
of the German reimbursement system: resource use of
rivaroxaban was included in the German DRG calcula-
tion scheme in 2011 [16]. Despite this potential reim-
bursement, hospitals need incentives to change theirprescription behaviour. These might not be present if
the expected patient health gain is accompanied by a
profit loss.
Complementing RECORD trials’ data with data from
the Advisory Committee Briefing Book for rivaroxaban
[25], the results of our analysis may be more precise
compared with previously published analyses in which
the data were based only on the RECORD trials [28,34].
Furthermore, the supplementation of probabilities, i.e.
asymptomatic DVT becoming symptomatic and the dif-
ferentiation of pre- and post-discharge VTE events, may
Table 8 Deterministic sensitivity analyses of parameters that have a large effect on the model results

















Base case 0.0070 31.8 18.0 2,569.3 0.0203 20.7 −27.2 dominance
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http://www.biomedcentral.com/1472-6963/12/192offer a more detailed and comprehensive assessment of
the clinical pathway of VTE events after MOS.
In our analyses, rivaroxaban was found to be more ef-
fective in the prevention of VTE events compared with
enoxaparin sodium. For German hospitals, which per-
form 210,000 THR and 175,000 TKR each year [35],
providing rivaroxaban would prevent 1,470 symptomatic
VTE events in the case of THR and 3,500 events in the
case of TKR. This corresponds to an annual SHI budget
impact of €3.7 million (expenditure) in the case of THR
and –€4.7 million (savings) in the case of TKR. With re-
spect to the cost-effectiveness of enoxaparin from the
SHI perspective, rivaroxaban was cost-saving after TKR
and thus a dominant strategy. However, with respect to
THR, there is still uncertainty as to whether rivaroxaban
is cost-effective.
Despite these results, German hospitals are financially
better off, accounting for savings through avoided VTE
events, if they continue prescribing enoxaparin sodium.
The cost-effectiveness acceptability curves that we pre-
sented might help hospitals in weighing image loss ver-
sus profit loss.
In terms of the effectiveness of rivaroxaban, our find-
ings are similar to the results of other published eco-
nomic models [28,34]. However, these models refer to
different settings (i.e. Canada and Ireland) and usedifferent effectiveness outcomes (i.e. quality-adjusted
life–years (QALYs) and life–years gained (LYG)).
In terms of costs, the analyses conclude that prophy-
laxis with rivaroxaban leads to cost savings after THR
and TKR from the healthcare perspective. Although this
corresponds with our TKR results, we did not observe
cost savings after THR. Apart from methodological rea-
sons [36], this might be because, in Germany, medical
drugs and innovations are more expensive than in many
other countries.
In our analysis, the additional cost for rivaroxaban is
estimated to be €2.60 per application, whereas McCullagh
et al. report additional costs of €0.05 in Ireland [28], and
additional costs of less than €0.50 were reported by
Diamantopoulos et al. in Canada [34]. In addition,
Diamantopoulos et al. calculated extra costs for the ad-
ministration of enoxaparin, and they included the costs of
long-term complications of VTE events in their analysis.
These VTE events result in higher long-term costs of
enoxaparin compared with rivaroxaban. McCullagh et al.
adopted data on clinical input estimates after THR from
the RECORD 2 trials, which provide a greater number of
avoided VTEs with rivaroxaban. However, we did not refer
to the RECORD 2 data as, in these trials, patients receive
rivaroxaban prophylaxis for 35 days whereas enoxaparin
was administered for only 14 days [12].
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procedures for VTE events as realistically as possible.
However, clinical pathways for prophylaxis and VTE
management may differ between hospitals and limit the
transferability of our results.
The model may appear to be limited in that the poten-
tial consequences of major bleeding events such as
stroke or death are not considered. However, with re-
spect to major bleeding events, no significant differences
were observed between rivaroxaban and enoxaparin so-
dium [11,13]. By modelling the consequences of major
bleeding events more explicitly, including costs and
effects, they would have been cancelled out within the
evaluation. However, there was still a need to include
major bleeding events in the model structure. If a major
bleeding event occurs, thrombosis prophylaxis stops im-
mediately, which reduces medical expenditure for rivar-
oxaban or enoxaparin sodium. For model consistency,
the same probability of a major bleeding event was ap-
plied for enoxaparin sodium and rivaroxaban prophy-
laxis. However, assuming unequal probabilities in the
given tree structure did not affect the results within a
sensitivity analysis (results not shown).
From the SHI perspective, the model may also appear
to be limited because the potential long-term conse-
quences of VTE such as recurrent VTE events and post-
thrombotic syndrome (PTS) are not modelled. However,
the incidence of long-term complications depends
greatly on the aetiology of DVT. There is no evidence
for the recurrence of VTE after MOS [37]. The same
has been confirmed for the PTS. There is no significant
difference in PTS incidence among patients with DVT
or PE after THR or TKR compared with patients with
no DVT history [38,39].
The use of drug prices from the ‘Rote Liste’ [29] might
be viewed critically. In Germany, each hospital negoti-
ates individual discounts with the pharmaceutical com-
panies. As discounts can vary significantly from hospital
to hospital, no representative average drug price can be
estimated. In addition, hospitals do not publish their
wholesale drug prices. Summarizing, it is not possible to
deduce drug prices from hospital data. Hence, the drug
prices given in our analysis may even lead to an overesti-
mation of costs.
However, the bias with respect to ‘Rote Liste’ prices
appears to be equal for each treatment alternative, and
uncertainty is covered within PSA.
A further limitation of this evaluation is that the main
effect is based on trial data. Although the study popula-
tion is similar in the case of TKR (mean age 69 years
(RECORD) versus 68 years (German hospitals)), in the
case of THR, the patients in everyday practice are sig-
nificantly older (63 years (RECORD) versus 72 years
(German hospitals)) [11,13,40].In the case of MOS, the DRG revenue includes aver-
age costs for all resource consumptions for a mean
hospitalization time of 12.4 days after THR and 12.7 days
after TKR. Daily costs vary from the beginning to the
end of a hospital stay, as the majority of diagnostic and
treatment measures are carried out within the first
2 days. However, as no precise data exist to estimate the
costs of one additional hospital day, we assumed a daily
cost rate based on a mean value according to the special
DRG revenue. Furthermore, we did not take into ac-
count the fact that fixed costs have to be paid regardless
of whether a bed is occupied or not. Finally, we did not
consider the occupancy rate, which in the case of full oc-
cupancy would lead to hospital losses, as it delays the
admission of further patients.
With respect to the health outcome, our analysis was
conducted with the effect measure ‘number of DVTs
averted’. This choice was made because the majority of
German decision makers, in particular the German Insti-
tute for Quality and Efficiency in Health Care (‘Institut
für Qualität und Wirtschaftlichkeit im Gesundheitswe-
sen’, IQWiG), prefer effectiveness measures other than
QALYs [41]. Furthermore, modelling QALYs would have
led to a higher degree of structural uncertainty, as mod-
elling a lifetime horizon would be substantial. In this
particular case, using QALYs appeared not to be essen-
tial in drawing the final conclusions.
Furthermore, we did not consider intangible costs
such as patients’ greater satisfaction with the oral admin-
istration of rivaroxaban resulting in better drug compli-
ance [42]. As increased compliance would also decrease
the number of post-operative VTE complications, our
model may even underestimate cost savings with rivar-
oxaban prophylaxis.
Even though we recommend further research to esti-
mate the model parameters more precisely, we believe
that the uncertainty of the results is depicted accurately
in our analysis. Apart from the results from the SHI per-
spective after THR, the results of our analysis are rela-
tively stable, coinciding with those of other analyses
[28,34].Conclusion
The use of rivaroxaban compared with enoxaparin
reduces VTE events for both THR and TKR and results
in cost savings from the SHI perspective for TKR. Based
on current DRGs, profits for hospitals will decrease with
the use of rivaroxaban. Considering its higher efficacy
and moderate price increase compared with enoxaparin,
incentives should be offered for German hospitals to
prescribe rivaroxaban. Although a DRG system might
give misleading incentives, these can be identified via a
multiple perspective evaluation.
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ANCOVA: analysis of covariance; AWMF: Association of the Scientific Medical
Societies (‘Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen
Fachgesellschaften’); CI: Confidence interval; CT: Computerized tomography;
DRG: Diagnosis related group; DVT: Deep vein thrombosis; EbM: German
Uniform Assessment Standard (‘Einheitlicher Bewertungsmaßstab’);
HIT: Heparin-induced thrombocytopenia; KBV: National Association of
Statutory Health Insurance Physicians (‘Kassenärztliche Bundesvereinigung’);
LMWHs: Low-molecular-weight heparins; LYG: Life–years gained;
Mg: Milligram; MOS: Major orthopaedic surgery; PE: Pulmonary embolism;
PSA: Probabilistic sensitivity analysis; QALYs: Quality-adjusted life–years;
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of
Glycaemia in Diabetes; S.C.: Subcutaneous; SHI: Statutory health insurance;
THR: Total hip replacement; TKR: Total knee replacement; VTE: Venous
thromboembolism.
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